A mutation in Mycobacterium tuberculosis rpoB gene confers rifampin resistance in three HIV-TB cases

Tuberculosis

Volumn 90, Issue 2, 2010, Pages 152-157

  Malhotra, Sangita ^a   Cook, Victoria J ^a,b   Wolfe, Joyce N ^c   Tang, Patrick ^a,b   Elwood, Kevin ^a,b   Sharma, Meenu K ^c,d  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

^c PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^d UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Mycobacterium tuberculosis; Rifampin resistant tuberculosis; rpoB

Indexed keywords

ETHAMBUTOL; ISONIAZID; MOXIFLOXACIN; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CASE REPORT; CODON; COMORBIDITY; DIRECTLY OBSERVED THERAPY; DRUG DOSE INCREASE; DRUG WITHDRAWAL; FEMALE; GENE INSERTION; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG TUBERCULOSIS; MALE; MILIARY TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; RELAPSE; RISK FACTOR; RPOB GENE; TREATMENT OUTCOME;

ADULT; ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; DRUG RESISTANCE, MICROBIAL; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; MUTATION; MYCOBACTERIUM TUBERCULOSIS; RIFAMPIN; SEQUENCE ANALYSIS, DNA; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

EID: 77950593250     PISSN: 14729792     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tube.2010.01.001     Document Type: Article

References (32)

1. Bloch A.B., Cauthen G.M., Onorato I.M., et al. Nationwide survey of drug-resistant tuberculosis in the United States. JAMA 271 (1994) 665-671
2. Mitchison D.A., and Nunn A.J. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis 133 (1986) 423-430
3. Musser J.M. Antimicrobial agent resistance in mycobacteria: molecular genetic insights. Clin Microbiol Rev 8 (1995) 496-514
4. Ridzon R., Whitney C.G., McKenna M.T., et al. Risk factors for rifampin mono-resistant tuberculosis. Am J Respir Crit Care Med 157 (1998) 1881-1884
5. Parsons L.M., Driscoll J.R., Taber H.W., and Salfinger M. Drug resistance in tuberculosis. Infect Dis Clin North Am 11 (1997) 905-928
6. Vernon A., Burman W., Benator D., Khan A., and Bozeman L. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium Lancet 353 (1999) 1843-1847
7. Sandman L., Schluger N.W., Davidow A.L., and Bonk S. Risk factors for rifampin-monoresistant tuberculosis: a case-control study. Am J Respir Crit Care Med 159 (1999) 468-472
8. Munsiff S.S., Joseph S., Ebrahimzadeh A., and Frieden T.R. Rifampin-monoresistant tuberculosis in New York city, 1993-1994. Clin Infect Dis 25 (1997) 1465-1467
9. Somoskovi A., Parsons L.M., and Salfinger M. The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis. Respir Res 2 (2001) 164-168
10. CLSI (formerly NCCLS). Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes; approved standard. CLSI (NCCLS) document M24-A (2003), CLSI (NCCLS), Wayne, Pennsylvania, USA
11. Telenti A., Imboden P., Marchesi F., et al. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 341 (1993) 647-650
12. McCammon M.T., Gillette J.S., Thomas D.P., et al. Detection of rpoB mutations associated with rifampin resistance in Mycobacterium tuberculosis using denaturing gradient gel electrophoresis. Antimicrob Agents Chemother 49 (2005) 2200-2209
13. Miller M.A., Thibert L., Desjardins F., Siddiqi S.H., and Dascal A. Testing of susceptibility of Mycobacterium tuberculosis to pyrazinamide: comparison of Bactec method with pyrazinamidase assay. J Clin Microbiol 33 (1995) 2468-2470
14. Steadham J.E., Stall S.K., and Simmank J.L. Use of the BACTEC system for drug susceptibility testing of Mycobacterium tuberculosis, M. kansasii, and M. avium complex. Diagn Microbiol Infect Dis 3 (1985) 33-40
15. Blackwood K.S., Burdz T.V., Turenne C.Y., Sharma M.K., Kabani A.M., and Wolfe J.N. Viability testing of material derived from Mycobacterium tuberculosis prior to removal from a containment level-III laboratory as part of a laboratory risk assessment program. BMC Infect Dis 5 (2005) 4
16. Turenne C.Y., Tschetter L., Wolfe J., and Kabani A. Necessity of quality-controlled 16S rRNA gene sequence databases: identifying nontuberculous Mycobacterium species. J Clin Microbiol 39 (2001) 3637-3648
17. Supply P., Lesjean S., Savine E., Kremer K., van Soolingen D., and Locht C. Automated high-throughput genotyping for study of global epidemiology of Mycobacterium tuberculosis based on mycobacterial interspersed repetitive units. J Clin Microbiol 39 (2001) 3563-3571
18. van Embden J.D., Cave M.D., Crawford J.T., et al. Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized methodology. J Clin Microbiol 31 (1993) 406-409
19. Pfyffer G.E., Bonato D.A., Ebrahimzadeh A., et al. Multicenter laboratory validation of susceptibility testing of Mycobacterium tuberculosis against classical second-line and newer antimicrobial drugs by using the radiometric BACTEC 460 technique and the proportion method with solid media. J Clin Microbiol 37 (1999) 3179-3186
20. Wolfe J.N., Blackwood-Antonation K.S., Sharma M.K., and Cook V.J. A case of acquired rifampin resistance in mycobacterium bovis bacillus calmette-guerin-induced cystitis: necessity for treatment guidelines. Can J Infect Dis Med Microbiol 17 (2006) 183-185
21. Korenromp E.L., Scano F., Williams B.G., Dye C., and Nunn P. Effects of human immunodeficiency virus infection on recurrence of tuberculosis after rifampin-based treatment: an analytical review. Clin Infect Dis 37 (2003) 101-112
22. March F., Garriga X., Rodriguez P., et al. Acquired drug resistance in Mycobacterium tuberculosis isolates recovered from compliant patients with human immunodeficiency virus-associated tuberculosis. Clin Infect Dis 25 (1997) 1044-1047
23. Peloquin C.A., Nitta A.T., Burman W.J., et al. Low antituberculosis drug concentrations in patients with AIDS. Ann Pharmacother 30 (1996) 919-925
24. Bishai W.R., Graham N.M., Harrington S., et al. Brief report: rifampin-resistant tuberculosis in a patient receiving rifabutin prophylaxis. N Engl J Med 334 (1996) 1573-1576
25. Bradford W.Z., Martin J.N., Reingold A.L., Schecter G.F., Hopewell P.C., and Small P.M. The changing epidemiology of acquired drug-resistant tuberculosis in San Francisco, USA. Lancet 348 (1996) 928-931
26. Havlir D.V., and Barnes P.F. Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med 340 (1999) 367-373
27. Gurumurthy P., Ramachandran G., Hemanth Kumar A.K., et al. Malabsorption of rifampin and isoniazid in HIV-infected patients with and without tuberculosis. Clin Infect Dis 38 (2004) 280-283
28. Kim B.J., Lee S.H., Lyu M.A., et al. Identification of mycobacterial species by comparative sequence analysis of the RNA polymerase gene (rpoB). J Clin Microbiol 37 (1999) 1714-1720
29. Scorpio A., Lindholm-Levy P., Heifets L., et al. Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 41 (1997) 540-543
30. Kasai H., Ezaki T., and Harayama S. Differentiation of phylogenetically related slowly growing mycobacteria by their gyrB sequences. J Clin Microbiol 38 (2000) 301-308
31. Niemann S., Harmsen D., Rusch-Gerdes S., and Richter E. Differentiation of clinical Mycobacterium tuberculosis complex isolates by gyrB DNA sequence polymorphism analysis. J Clin Microbiol 38 (2000) 3231-3234
32. Widjojoatmodjo M.N., Fluit A.C., and Verhoef J. Molecular identification of bacteria by fluorescence-based PCR-single-strand conformation polymorphism analysis of the 16S rRNA gene. J Clin Microbiol 33 (1995) 2601-2606